

Treatment of Ankylosing Spondylitis

DANIEL O. CLEGG

ABSTRACT. Ankylosing spondylitis (AS) is a condition characterized by inflammatory back pain and associated with considerable disability and diminished quality of life in affected individuals. The condition is undertreated in part due to a delay in diagnosis and limited therapeutic interventions. Although traditional treatment approaches (physical therapy, exercise, patient education, nonsteroidal antiinflammatory drugs) remain important components of the management of AS, the demonstrated efficacy of tumor necrosis factor- α (TNF- α) antagonists such as etanercept and infliximab have allowed clinicians to more effectively manage this condition. These targeted therapies have demonstrated rapid and consistent effectiveness in reducing the axial and peripheral symptoms of AS, slowing disease progression, and improving patient function and quality of life. Appropriate and timely use of TNF- α antagonists offers additional options for patients with active AS who are inadequately controlled with conventional treatment. (J Rheumatol 2006;33 Suppl 78:24-31)

Key Indexing Terms:

ANKYLOSING SPONDYLITIS
DISEASE MODIFYING ANTIRHEUMATIC DRUGS

TREATMENT
BIOLOGIC PRODUCTS

INTRODUCTION

Ankylosing spondylitis (AS) is an inflammatory condition whose main clinical feature is inflammatory back pain caused by sacroiliitis and spondylitis¹. Patients with AS may also have peripheral arthritis, enthesitis, and acute anterior uveitis¹. AS is associated with considerable disability, reduced quality of life, and high costs in terms of direct medical expenses and indirect costs due to lost wages and productivity²⁻⁷. Patients with AS report similar pain and functional disability as those with rheumatoid arthritis², and leave the labor force at a 3-fold higher rate than the general population⁸.

Until recently, the options available to clinicians for the treatment of AS have been limited, with patient education, physical therapy, and nonsteroidal antiinflammatory drugs (NSAID) being the mainstay of effective therapy. The advent of tumor necrosis factor- α (TNF- α) antagonists represents a breakthrough in the treatment of AS. Nonetheless, despite the development of these more effective treatments that can slow AS disease progression, there is still an unmet need in the management of this

condition due to the suboptimal use of these therapies. This article will review the treatment of AS.

UNDERTREATMENT/SUBOPTIMAL TREATMENT

As discussed elsewhere in this supplement series, the diagnosis of AS is frequently missed or substantially delayed, particularly in the primary care setting⁹. Disease onset is insidious, making diagnosis difficult before the occurrence of irreversible damage¹⁰. A mean delay of 10 years from time of first symptoms to a definitive diagnosis has been reported^{11,12}. This delay also means a delay in treatment, allowing significant disease progression to occur.

In patients with AS, severe spinal restriction (< 3 cm of lumbar movement and < 20° of cervical thoracic movement) occurs in up to 41% of patients, and the majority (81%) of these patients are severely restricted within 10 years of onset¹³. It has also been shown that spinal progression is a function of disease duration¹⁴. Therefore, management of the early stages of AS is critical for slowing disease progression.

TRADITIONAL APPROACHES TO TREATMENT

Both nonpharmacologic and pharmacologic interventions are important in the management of AS. Important nonpharmacologic components of AS management include physical therapy, exercise (including muscle conditioning along with instruction), and encouragement of appropriate posture¹⁵. Exercise/physical therapy programs have been shown to improve measures of pain, spinal mobility, patient function, and well-being, with supervised programs being more effective than individual at-home programs¹⁶⁻²². For example, in a randomized trial in 144 patients with AS, supervised group physiotherapy (hydrotherapy, exercises, and sporting activities) was more effective at improving spinal mobility, fitness,

From the Rheumatology Section, Salt Lake City Veterans Health Care System, University of Utah School of Medicine, Salt Lake City, Utah, USA.

Funding for this supplement series was provided by Amgen, Inc. and Wyeth Research.

D.O. Clegg, MD.

Address reprint requests to Dr. D.O. Clegg, Rheumatology Section, Salt Lake City Veterans Health Care System, University of Utah School of Medicine, 50 North Medical Drive, Room 4B181, Salt Lake City, UT. E-mail: daniel.clegg@hsc.utah.edu

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2006. All rights reserved.

and patient reported global health than an individualized program²⁰. In addition, patient education/support programs have been shown to improve patient perception of well-being^{23,24}. For example, a short intensive course (12 hours of education over 2 consecutive days) with sessions on AS disease information, exercises, posture, and home checks for monitoring mobility produced improvements in depression and self-efficacy (daily ability to manage pain, fatigue, and physical functioning) at 3 weeks, with a trend toward continued improvement at 6 months²³. The frequency and range of types of exercise both significantly decreased over time, underscoring the importance of continued followup and reinforcement of exercise programs in the AS population.

NSAID are the foundation of management of AS, and are currently the first-line drugs for initial management of pain and stiffness. In mostly short-term studies (up to 3 months), conventional NSAID produced significant improvements in symptoms in patients with AS, including spinal pain, duration of morning stiffness, night pain, immobility, stiffness, and peripheral pain²⁵⁻³⁷.

More recently, selective cyclooxygenase-2 (COX-2) inhibitors have been evaluated in patients with AS^{38,39}. Although etoricoxib is no longer available, a 6-week study in 387 patients with AS treated with etoricoxib 90 mg/day or 120 mg/day showed similar efficacy (spine pain, functionality, and patient global assessment of disease activity) to naproxen 1000 mg/day, and both agents had significantly greater efficacy than placebo³⁸. These improvements were maintained over a 52-week double-blind continuation of the 6-week study³⁸. Similarly, 6 weeks of treatment with celecoxib 100 mg twice daily showed similar efficacy to ketoprofen 100 mg twice daily and significantly greater efficacy than placebo in terms of global pain intensity and functional impairment in 246 patients with AS³⁹. After 6 weeks of therapy, patients were randomly assigned either continuous or as-needed treatment with celecoxib 100 mg twice daily for 2 years (allowed to increase to 200 mg twice daily at patient's discretion)⁴⁰. Despite a similar effect on measures of pain, inflammation, and spinal mobility, continuous use of celecoxib (or other NSAID taken continuously) slowed radiographic progression to a significantly greater degree than intermittent use after 2 years⁴⁰.

Disease modifying antirheumatic drugs (DMARD) are a potential second-line therapy but their efficacy in AS is unproven. There has been a lack of consistent results in clinical trials with DMARD⁴¹⁻⁴⁷. Sulfasalazine has generally demonstrated efficacy at improving AS-associated peripheral arthritis, but not back pain^{42,48,49}. For example, a 36-week study of 264 patients with chronic longstanding AS (mean duration 18.5 years) reported no significant differences between sulfasalazine 2000 mg/day and placebo recipients for any clinical measures of effica-

cy, including physician and patient global assessment, morning stiffness, back pain, night pain, duration of morning stiffness, spondylitis functional index, and joint pain/tenderness⁴⁹. Another study showed some improvement in clinical symptoms (morning stiffness and chest expansion) relative to placebo following 26 weeks of treatment with sulfasalazine \leq 3000 mg/day⁵⁰. However, a subgroup analysis in patients with AS reported no significant difference in axial response rates between sulfasalazine and placebo in patients with axial disease only or in patients with combined axial/peripheral disease, but did show a peripheral response in patients with axial/peripheral disease⁴⁹. In a combined analysis of patients with seronegative spondyloarthropathies (264 AS, 221 psoriatic arthritis, and 134 reactive arthritis), sulfasalazine produced better treatment response rates (composite index of 4 outcome measures) in patients with peripheral arthritis than in those with exclusively axial disease⁴⁸.

Methotrexate (MTX) also has not demonstrated consistent efficacy for AS-associated back pain, and has shown inconsistent efficacy for peripheral disease^{41,47,51}. In a small study (n = 51), there were no significant differences in efficacy observed between naproxen and MTX plus naproxen after 1 year⁴⁷. Another small study (n = 35) showed some benefit with MTX therapy over placebo after 24 weeks for a composite index of improvement [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Health Assessment Questionnaire for Spondyloarthropathies, severity of morning stiffness, physical well-being, and physician and patient global assessment of disease activity], with a statistical difference between the 2 groups observed only at Week 24⁵¹. Both of these studies used relatively low dosages of MTX (7.5 mg/wk).

Leflunomide was not effective for axial manifestations of AS, but may provide some benefit for peripheral arthritis. In a 6-month open-label study in 20 patients with AS, treatment with leflunomide (100 mg/day for 3 days, then 20 mg/day for 6 months) did not produce significant improvement in a number of measures, including BASDAI, BASFI, patient and physician global assessment, Medical Outcome Study Short Form-36 General Health Survey (SF-36) mental component, and C-reactive protein⁵². Significant improvement in peripheral arthritis, as assessed by the mean number of inflamed joints, was noted in this study.

NEW APPROACHES TO TREATMENT

With the advent of biologic agents, it is now possible to slow disease progression in AS rather than simply allay symptoms. TNF- α is a proinflammatory cytokine involved in the pathogenesis of AS and other spondy-

Table 1. Summary of randomized, placebo-controlled trials of tumor necrosis factor- α inhibitors in patients with ankylosing spondylitis.

Study	No. of Patients (study duration)	Primary Efficacy Endpoint	Results, %	p vs Placebo
Etanercept 25 twice weekly				
Gorman ⁶³	40 (4 mo)	Composite index responders (20% improvement in 3 of 5 outcome measures*)	Etanercept 80 Placebo 30	0.004
Brandt ⁶⁴	30 (6 wks)	$\geq 50\%$ improvement in BASDAI	Etanercept 57 Placebo 6	0.004
Calin ⁶⁷	84 (12 wks)	ASAS20 responders	Etanercept 60 Placebo 23	< 0.0001
Davis ⁶⁶	277 (24 wks)	ASAS20 responders	Etanercept 57 Placebo 22	< 0.0001
Infliximab 5 mg/kg at weeks 0, 2, and 6, then every 6 weeks				
Braun ⁷⁰	35 (12 wks)	$\geq 50\%$ improvement in BASDAI	Infliximab 53 Placebo 9	< 0.0001
van den Bosch ⁷¹	40 (12 wks)	Global disease activity (0-100 mm) scale	Patient assessment: Infliximab 18 mm Placebo 69 mm	≤ 0.001
			Physician assessment: Infliximab 16.5 mm Placebo 72 mm	≤ 0.001
van der Heijde ⁷² (ASSERT)	279 (24 wks)	ASAS20 responders	Infliximab 61.2 Placebo 19.2	< 0.001
Adalimumab 40 mg every other week				
Davis ⁵⁹ (ATLAS)	315 (24 wks)	ASAS5/6 criteria	Adalimumab 44.2 Placebo 13.1	≤ 0.001

*Duration of morning stiffness, degree of nocturnal spine pain, BASFI, patient global assessment of disease activity, and score for joint swelling. ASAS20: 20% improvement in the Assessments in Ankylosing Spondylitis response criteria; ASAS5/6: ASAS questions 5 and 6 criteria; ASSERT: Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy; ATLAS: Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index.

loarthropathies^{53,54}. Etanercept and infliximab are TNF- α antagonists approved by the US Food and Drug Administration for the treatment of AS^{55,56}, and both drugs have demonstrated rapid and sustained efficacy in the treatment of this condition. Adalimumab⁵⁷ is another TNF- α antagonist in development for the treatment of AS, with preliminary evidence of similar efficacy⁵⁸⁻⁶².

Etanercept. Etanercept 25 mg twice weekly has demonstrated consistent efficacy in a number of clinical trials in patients with AS (Table 1). In a 4-month study, the percentage of responders (composite index of outcome measures) was significantly higher in etanercept than placebo recipients (80% vs 30%; $p = 0.004$)⁶³. In a 6-month extension of this trial in which all patients received etanercept, these results were maintained in the original etanercept group and patients who had originally received placebo achieved an 80% response rate within 1 month of initiating etanercept treatment⁶³. Similar results were observed in a 24-week study, which had a 6-week placebo-controlled portion followed by 6 weeks of

continued treatment in the etanercept group and 12 weeks' treatment with etanercept in the placebo group (all patients received 12 weeks' total therapy with etanercept)⁶⁴. Patient function, spine mobility, and quality of life improved with treatment, and one-third of patients experienced a partial remission [Assessments in Ankylosing Spondylitis (ASAS) criteria] after 12 weeks of etanercept treatment. After drug cessation, 75% of patients experienced relapse of symptoms within 3 months⁶⁴. A 54-week open-label extension of this study was conducted in 26 patients who had discontinued etanercept per study protocol (for a mean 26.8 weeks) and who had developed high disease activity⁶⁵. Eighty-eight percent of patients were still receiving etanercept at the end of the extension period, 58% had a $\geq 50\%$ improvement in BASDAI, and 31% were in partial remission⁶⁵. These results are consistent with the results obtained in the initial 12-week study⁶⁴.

The proportions of 12-week responders (ASAS20) were similar in 2 larger studies of etanercept (Table 1)^{66,67}. All ASAS components, including spine mobility and patient

global assessment, were significantly improved with etanercept treatment. In a large AS study (n = 277), 24 weeks of treatment with etanercept produced a significantly higher percentage of ASAS20 responders than placebo (57% vs 22%; p < 0.0001)⁶⁶. An open-label extension of this study showed sustained efficacy with etanercept treatment: 70% of patients who had previously received etanercept and 78% of patients who had previously received placebo achieved an ASAS20 response at 96 weeks⁶⁸. Spinal magnetic resonance imaging (MRI) has also shown that etanercept treatment produces regression in spine inflammation (improvement of 54% at 12 weeks)⁶⁹.

Infliximab. Infliximab 5 mg/kg at Weeks 0, 2, and 6 (and then every 6 weeks thereafter in studies with a duration > 12 weeks) demonstrated consistent efficacy in patients with AS for a number of different primary efficacy measures (Table 1)⁷⁰⁻⁷². In the study presented by Braun, *et al*, partial remission was observed in about 20% of infliximab-treated patients compared with about 3% of patients in the placebo group⁷⁰.

The longterm efficacy of infliximab for AS has been evaluated in an open-label extension of the Braun, *et al*⁷⁰ study. Patients continued to receive infliximab 5 mg/kg every 6 weeks after the induction dosing phase; data for 54 weeks⁷³, 102 weeks⁷⁴, and 156 weeks⁷⁵ are available. Of the 69 patients who entered the open-label extension, 54 continued to receive infliximab at 54 weeks⁷³. Forty-seven percent of patients who had received continuous infliximab and 51% of patients who received placebo for 12 weeks followed by infliximab were BASDAI50 responders at Week 54, and partial remission was reported in 18% and 17% of patients, respectively⁷³. These results were maintained in the 49 patients who completed 102 weeks of the study (41% and 49%, respectively)⁷⁴, and in the 46 patients who completed 156 weeks (47% and 43%, respectively)⁷⁶. An assessment of 41 patients from the 2-year analysis⁷⁴ showed a slowing of radiographic damage in infliximab-treated patients relative to an untreated cohort⁷⁷.

In the large Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) study (n = 279), 24 weeks of treatment with

Table 2. Summary of European guidelines and United States modifications for the use of tumor necrosis factor- α inhibitors in patients with AS. Adapted from the Spondylitis Association of America¹⁵, with permission; and updated based on 2006 ASAS guidelines by Braun, *et al*⁸⁴.

ASAS	US Modifications
Diagnosis	
Modified New York criteria	Modified New York criteria
Disease Activity	
BASDAI score > 4 (0–10) scale) and Physician Global Assessment by “expert” opinion, yes/no	BASDAI score > 4 (0–10) scale) and Physician Global Assessment of ≥ 2 on Likert scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe
Previous Treatment	
Failure by lack of response or intolerability to > 2 NSAID for 3 mo for all clinical 3 presentations: axial, peripheral arthritis, and enthesitis. Patients with peripheral arthritis also having a lack of response to sulfasalazine. Patients with enthesitis must have failed appropriate local treatment	Failure by lack of response or intolerability to > 2 NSAID for 3 mo for all clinical 3 presentations: axial, peripheral arthritis, and enthesitis. Patients with peripheral arthritis must have had a lack of response or intolerability to > 1 DMARD (sulfasalazine preferred) for peripheral arthritis. Not required for axial disease or enthesitis (corticosteroid injection not required)
Dosing	
Etanercept 25 mg SQ twice a week or 50 mg once weekly* Infliximab 5 mg/kg IV every 6-8 weeks	Etanercept 25 mg SQ twice a week or 50 mg once weekly Infliximab 5 mg/kg IV every 6-8 weeks
Responder Criteria	
50% improvement of BASDAI or absolute change of 2 on 0–10 cm scale and “expert” opinion	Improvement in BASDAI by at least 2 units and Physician Global Assessment of > 1 unit
Time of Evaluation, wks	
6 to 12	6-8
TB Precaution	
Use country-specific guidelines	TB screening and treatment per American Thoracic Association recommendations

*The 50-mg once weekly alternative dosing regimen has not yet been approved in Europe for AS. On February 23, 2006, this dose for AS was recommended for approval by the Committee for Medicinal Products for Human Use. ASAS: Assessments in Ankylosing Spondylitis; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; DMARD: disease-modifying antirheumatic drug; IV intravenously; NSAID: nonsteroidal antiinflammatory drugs; SQ: subcutaneously; TB: tuberculosis.

infliximab produced a significantly higher percentage of ASAS20 responders than placebo (61.2% vs 19.2%; $p < 0.001$), and demonstrated significant improvement in a number of other measures, including BASDAI, BASFI, chest expansion, and the physical component score of the SF-36⁷². Recent 30-week data indicated that infliximab in combination with MTX produced significantly greater reductions in BASDAI scores than MTX alone in 42 patients with AS, and significantly greater regression in enthesitis/osteitis as assessed by MRI⁷⁸. The addition of MTX did not appear to extend the dosing interval for infliximab, however, as evidenced by the occurrence of disease flares 8 weeks after the last infliximab infusion⁷⁸.

Adalimumab. Adalimumab, another TNF- α antagonist, is under investigation for the treatment of AS. In a small ($n = 14$) open-label 20-week study, adalimumab 40 mg every other week produced significant improvement in spinal symptoms in patients with AS⁷⁹. Preliminary results of the phase 3 Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS) in 315 patients showed that a significantly higher proportion of adalimumab (40 mg every other week) than placebo recipients achieved ASAS partial remission status (21.6% vs 6.5%) and ASAS5/6 criteria (44.2% vs 13.1%) (both $p \leq 0.001$)⁵⁹.

Safety. In the clinical trials discussed above, the TNF- α antagonists were well tolerated, with the rates of adverse events generally being similar in active drug and placebo groups. Injection site reactions, upper respiratory tract infections, and accidental injury were reported in significantly more etanercept- than placebo-treated patients⁶⁶. Infliximab was generally as well tolerated in the large AS study: elevated transaminase levels were reported in more infliximab than placebo recipients⁷². Although the rate of infusion reactions was similar for infliximab and placebo in this AS study, clinical studies have reported a higher rate of this adverse event in infliximab-treated patients⁵⁶. The adalimumab data from the ATLAS study were published in abstract form, and no specific adverse event details were provided for these AS patients (adverse events were comparable between the adalimumab and placebo groups)⁵⁹.

General precautions with the use of TNF- α antagonists include (1) an increased risk of opportunistic infections, possible increased risk of lymphoma, and hepatotoxicity (infliximab); and (2) avoidance of use in patients with pre-existing demyelinating disease or moderate to severe heart failure^{55-57,80,81}. Rare cases of tuberculosis have been reported in patients receiving TNF- α antagonists, including etanercept⁵⁵. Infliximab and adalimumab carry a black-box warning highlighting the risk for tuberculosis^{56,57}.

Guidelines for use of TNF- α antagonists. There are a number of published treatment guidelines for biologic therapies in AS^{15,82-85}. Many patients with AS meet the criteria for anti-TNF- α treatment (reflecting severe disease) in established guidelines, but do not receive these agents⁸⁶. Recently, a survey of AS patients indicated that nearly two-thirds of patients had poor functional status and quality of life (BASDAI score ≥ 40) and would meet the British Society of Rheumatology criteria for TNF- α antagonist use⁸⁶. The results of this survey, conducted between 2001 and 2003 (just as biologics were being introduced for AS), suggested that there may be a substantial unmet need for effective treatment in AS.

An overview of guidelines for the use of TNF- α antagonists, including the US modifications of European guidelines, is presented in Table 2^{15,84}.

CONCLUSIONS

Ankylosing spondylitis is associated with significant pain, functional disability, and diminished quality of life. This disease represents a therapeutic challenge for clinicians because of its insidious onset that often results in delays in recognition. Radiologic damage may occur early in the course of AS, underscoring the importance of early recognition and appropriate treatment. The major goal of therapy of inflammatory conditions such as AS is to slow disease progression and improve function.

Conventional approaches to the management of AS, such as physical therapy, exercise, patient education, and NSAID therapy remain important components of AS treatment. Traditional DMARD, such as sulfasalazine and MTX, have not consistently shown benefit, particularly for axial manifestations. The development of targeted anti-TNF therapies that provide disease control has heralded a new era for the treatment of AS and provided hope for many patients suboptimally controlled. Etanercept and infliximab, the 2 TNF- α antagonists currently approved for the treatment of AS, have demonstrated rapid and consistent effectiveness in reducing the axial and peripheral symptoms, and improving patient function and quality of life. Data are also available to support the longterm use of these agents. The established efficacy and safety profiles of the TNF- α antagonists makes this class of agents an important new addition to the previously limited armamentarium available to rheumatologists for the treatment of AS.

ACKNOWLEDGMENT

The author wishes to thank Rick Davis, MS, RPh, whose work was funded by Amgen, Inc., for providing assistance in the drafting of this report, and Scott Baumgartner, MD, of Amgen, Inc., for contributing to the concept development.

REFERENCES

1. van der Linden S, van der Heijde D, Braun J. Ankylosing spondylitis. In: Harris EJ, Budd R, Firestein GS, Genovese MC, Sargent JS, Sledge CB, editors. *Kelley's textbook of rheumatology*. 7th ed. Philadelphia: Elsevier Saunders; 2005:1125-41.
2. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis — results from the German rheumatological database. German Collaborative Arthritis Centers. *J Rheumatol* 2000;27:613-22.
3. Doward LC, Spoorenberg A, Cook SA, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. *Ann Rheum Dis* 2003;62:20-6.
4. Bostan EE, Borman P, Bodur H, Barca N. Functional disability and quality of life in patients with ankylosing spondylitis. *Rheumatol Int* 2003;23:121-6.
5. Ozgul A, Peker F, Taskaynatan MA, Tan AK, Dincer K, Kalyon TA. Effect of ankylosing spondylitis on health-related quality of life and different aspects of social life in young patients. *Clin Rheumatol* 2006;25:168-74. Epub 2005 Aug 10.
6. Chorus AM, Boonen A, Miedema HS, van der Linden S. Employment perspectives of patients with ankylosing spondylitis. *Ann Rheum Dis* 2002;61:693-9.
7. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. *Arthritis Rheum* 2002;46:223-31.
8. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. *Ann Rheum Dis* 2001;60:353-8.
9. Boyer GS, Templin DW, Bowler A, et al. A comparison of patients with spondyloarthropathy seen in specialty clinics with those identified in a communitywide epidemiologic study. Has the classic case misled us? *Arch Intern Med* 1997;157:2111-7.
10. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. *Ann Rheum Dis* 2002;61 Suppl 3:iii8-18.
11. Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. *Curr Opin Rheumatol* 2000;12:239-47.
12. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. *Rheumatol Int* 2003;23:61-6.
13. Carette S, Graham D, Little H, Rubenstein J, Rosen P. The natural disease course of ankylosing spondylitis. *Arthritis Rheum* 1983;26:186-90.
14. Brophy S, Mackay K, Al-Saidi A, Taylor G, Calin A. The natural history of ankylosing spondylitis as defined by radiological progression. *J Rheumatol* 2002;29:1236-43.
15. Spondylitis Association of America. Guidelines for the use of anti-TNF therapy in patients with ankylosing spondylitis. Available from: http://www.spondylitis.org/physician_resources/guidelines.aspx. Accessed May 29, 2006.
16. Sweeney S, Taylor G, Calin A. The effect of a home based exercise intervention package on outcome in ankylosing spondylitis: a randomized controlled trial. *J Rheumatol* 2002;29:763-6.
17. Kraag G, Stokes B, Groh J, Helewa A, Goldsmith C. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis — a randomized controlled trial. *J Rheumatol* 1990;17:228-33.
18. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. *Cochrane Database Syst Rev* 2004;CD002822.
19. Hidding A, van der Linden S, de Witte L. Therapeutic effects of individual physical therapy in ankylosing spondylitis related to duration of disease. *Clin Rheumatol* 1993;12:334-40.
20. Hidding A, van der Linden S, Boers M, et al. Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial. *Arthritis Care Res* 1993;6:117-25.
21. van Tubergen A, Landewe R, van der Heijde D, et al. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. *Arthritis Rheum* 2001;45:430-8.
22. van Tubergen A, Hidding A. Spa and exercise treatment in ankylosing spondylitis: fact or fancy? *Best Pract Res Clin Rheumatol* 2002;16:653-66.
23. Barlow JH, Barefoot J. Group education for people with arthritis. *Patient Educ Couns* 1996;27:257-67.
24. Basler HD, Rehfish HP. Cognitive-behavioral therapy in patients with ankylosing spondylitis in a German self-help organization. *J Psychosom Res* 1991;35:345-54.
25. Shipley M, Berry H, Bloom B. A double-blind cross-over trial of indomethacin, fenoprofen and placebo in ankylosing spondylitis, with comments on patient assessment. *Rheumatol Rehabil* 1980;19:122-5.
26. Rejholec V, Vapaatalo H, Tokola O, Gothoni G. Tolfenamic acid in ankylosing spondylarthritis: a double-blind comparison to indomethacin. *Scand J Rheumatol Suppl* 1980;36:1-7.
27. Bird HA, Rhind VM, Pickup ME, Wright V. A comparative study of benoxaprofen and indomethacin in ankylosing spondylitis. *J Rheumatol* 1980;6 Suppl:139-42.
28. Burry HC, Siebers R. A comparison of flurbiprofen with naproxen in ankylosing spondylitis. *NZ Med J* 1980;92:309-11.
29. Wordsworth BP, Ebringer RW, Coggins E, Smith S. A double-blind cross-over trial of fenoprofen and phenylbutazone in ankylosing spondylitis. *Rheumatol Rehabil* 1980;19:260-3.
30. Sydnos OA. Comparison of piroxicam with indomethacin in ankylosing spondylitis: a double-blind crossover trial. *Br J Clin Pract* 1981;35:40-4.
31. Charlot J, Villiaume J. A comparative study of benoxaprofen and ketoprofen in ankylosing spondylitis. *Eur J Rheumatol Inflamm* 1982;5:277-81.
32. Esdaile J, Rothwell R, MacLaughlin K, Percy J, Hawkins D. Double-blind comparison of tolmetin sodium and indomethacin in ankylosing spondylitis. *J Rheumatol* 1982;9:69-74.
33. Lehtinen K, Kaarela K, Makisara P, Holttinen K, Gordin A. Tolerability and efficacy of a slow-release indomethacin tablet in ankylosing spondylitis. *Br J Rheumatol* 1984;23:52-6.
34. Bird HA, Le Gallez P, Astbury C, Looi D, Wright V. A parallel group comparison of toxicam and piroxicam in patients with ankylosing spondylitis. *Pharmatherapeutica* 1986;4:457-62.
35. Calabro JJ. Efficacy of diclofenac in ankylosing spondylitis. *Am J Med* 1986;80:58-63.
36. Franssen MJ, Gribnau FW, van de Putte LB. A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis. *Clin Rheumatol* 1986;5:210-20.
37. Khan MA. A double blind comparison of diclofenac and indomethacin in the treatment of ankylosing spondylitis. *J Rheumatol* 1987;14:118-23.
38. van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. *Arthritis Rheum* 2005;52:1205-15.
39. Dougados M, Behier JM, Jolchine I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. *Arthritis Rheum* 2001;44:180-5.
40. Wanders A, Heijde D, Landewe R, et al. Nonsteroidal

- antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. *Arthritis Rheum* 2005;52:1756-65.
41. Chen J, Liu C. Methotrexate for ankylosing spondylitis. *Cochrane Database Syst Rev* 2004;CD004524.
 42. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. *Arthritis Rheum* 1995;38:618-27.
 43. Thomson GT, Thomson BR, Thomson KS, Ducharme JS. Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. *J Rheumatol* 2000;27:714-8.
 44. Taggart A, Gardiner P, McEvoy F, Hopkins R, Bird H. Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study. *Arthritis Rheum* 1996;39:1400-5.
 45. Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. *Clin Rheumatol* 2000;19:114-7.
 46. Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM. Methotrexate in the treatment of ankylosing spondylitis. *Scand J Rheumatol* 2000;29:160-2.
 47. Altan L, Bingol U, Karakoc Y, Aydinler S, Yurtkuran M. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. *Scand J Rheumatol* 2001;30:255-9.
 48. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. *Arthritis Rheum* 1999;42:2325-9.
 49. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. *Arthritis Rheum* 1996;39:2004-12.
 50. Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. *Arthritis Rheum* 1988;31:1111-6.
 51. Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, Munoz-Valle JF, Gamez-Nava JI. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. *J Rheumatol* 2004;31:1568-74.
 52. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. *Ann Rheum Dis* 2005;64:124-6.
 53. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. *Arthritis Rheum* 1995;38:499-505.
 54. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. *Ann Rheum Dis* 2005;64 Suppl 2:ii26-9.
 55. Enbrel® (etanercept). Full prescribing information. Thousand Oaks, CA: Immunex Corporation (marketed by Amgen and Wyeth Pharmaceuticals); 2005.
 56. Remicade® (infliximab). Full prescribing information. Malvern, PA: Centocor, Inc.; 2005.
 57. Humira® (adalimumab). Full prescribing information. North Chicago, IL: Abbott Laboratories; 2005.
 58. Haibel H, Brandt H, Baraliakos X, et al. Adalimumab in the treatment of active ankylosing spondylitis: results of an open-label, 52-week trial. In: *The Annual European Congress of Rheumatology*; 2005 June 8-11; Vienna, Austria; 2005.
 59. Davis J, Kivitz A, Schiff M, et al. Major clinical response and partial remission in ankylosing spondylitis subjects treated with adalimumab: the ATLAS trial [abstract]. *Arthritis Rheum* 2005;52 Suppl:S208-9.
 60. van der Heijde D, Luo M, Matsumoto A, et al. Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis — the ATLAS trial [abstract]. *Arthritis Rheum* 2005;52 Suppl:S211.
 61. Maksymowych W, Rahman P, Keystone E, Wong R, Inman R, M03-606 Study Group. Efficacy of adalimumab in active ankylosing spondylitis (AS) — results of the Canadian AS study [abstract]. *Arthritis Rheum* 2005;52 Suppl:S217.
 62. van der Heijde D, Kivitz A, Schiff M, et al. Adalimumab therapy results in significant reduction of signs and symptoms in subjects with ankylosing spondylitis: the ATLAS trial [abstract]. *Arthritis Rheum* 2005;52 Suppl:S281.
 63. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. *N Engl J Med* 2002;346:1349-56.
 64. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. *Arthritis Rheum* 2003;48:1667-75.
 65. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. *Rheumatology Oxford* 2005;44:342-8.
 66. Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. *Arthritis Rheum* 2003;48:3230-6.
 67. Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. *Ann Rheum Dis* 2004;63:1594-600.
 68. Davis JC, van der Heijde DM, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. *Ann Rheum Dis* 2005;64:1557-62.
 69. Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. *Arthritis Rheum* 2005;52:1216-23.
 70. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. *Lancet* 2002;359:1187-93.
 71. Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. *Arthritis Rheum* 2002;46:755-65.
 72. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). *Arthritis Rheum* 2005;52:582-91.
 73. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. *Arthritis Rheum* 2003;48:2224-33.
 74. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. *Ann Rheum Dis* 2005;64:229-34.
 75. Baraliakos X, Listing J, Brandt J, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. *Arthritis Res Ther* 2005;7:R439-44.
 76. Braun J, Baraliakos X, Brandt J, et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. *Rheumatology Oxford* 2005;44:670-6.

77. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. *Ann Rheum Dis* 2005;64:1462-6.
78. Marzo-Ortega H, McGonagle D, Jarrett S, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. *Ann Rheum Dis* 2005;64:1568-75.
79. Haibel H, Brandt H, Rudwaleit M, et al. Efficacy and safety of adalimumab in the treatment of active ankylosing spondylitis: preliminary results of an open-label, 20-week trial [abstract]. *Arthritis Rheum* 2004;50 Suppl:S217.
80. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. *Drug Saf* 2004;27:307-24.
81. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF. Tuberculosis associated with therapy against tumor necrosis factor alpha. *Arthritis Rheum* 2005;52:2968-74.
82. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. *Ann Rheum Dis* 2003;62:817-24.
83. Keat A, Barkham N, Bhalla A, et al. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. *Rheumatology Oxford* 2005;44:939-47.
84. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. *Ann Rheum Dis* 2006;65:316-20.
85. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis* 2006;65:442-52.
86. Barkham N, Kong KO, Tennant A, et al. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. *Rheumatology Oxford* 2005;44:1277-81.